Abbott Laboratories $ABT Shares Purchased by Private Wealth Partners LLC

Private Wealth Partners LLC boosted its position in shares of Abbott Laboratories (NYSE:ABT) by 57.5% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 32,949 shares of the healthcare product maker’s stock after acquiring an additional 12,025 shares during the period. Private Wealth Partners LLC’s holdings in Abbott Laboratories were worth $4,413,000 as of its most recent filing with the SEC.

Several other hedge funds have also modified their holdings of the company. IMG Wealth Management Inc. lifted its position in shares of Abbott Laboratories by 759.1% during the 2nd quarter. IMG Wealth Management Inc. now owns 189 shares of the healthcare product maker’s stock valued at $26,000 after buying an additional 167 shares in the last quarter. Cloud Capital Management LLC acquired a new position in Abbott Laboratories during the third quarter worth $29,000. Anfield Capital Management LLC lifted its holdings in Abbott Laboratories by 81.3% during the second quarter. Anfield Capital Management LLC now owns 232 shares of the healthcare product maker’s stock valued at $32,000 after purchasing an additional 104 shares in the last quarter. Delos Wealth Advisors LLC purchased a new stake in shares of Abbott Laboratories during the second quarter worth about $32,000. Finally, Copia Wealth Management acquired a new position in shares of Abbott Laboratories during the 3rd quarter worth about $38,000. 75.18% of the stock is owned by hedge funds and other institutional investors.

Abbott Laboratories Price Performance

Shares of ABT stock opened at $109.31 on Friday. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.70 and a quick ratio of 1.24. The company has a market capitalization of $190.08 billion, a PE ratio of 29.39, a price-to-earnings-growth ratio of 1.69 and a beta of 0.72. The firm’s 50-day moving average is $122.77 and its two-hundred day moving average is $127.49. Abbott Laboratories has a 12 month low of $105.27 and a 12 month high of $141.23.

Abbott Laboratories (NYSE:ABT) last announced its quarterly earnings results on Thursday, January 22nd. The healthcare product maker reported $1.50 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $1.50. The business had revenue of $11.46 billion during the quarter, compared to the consensus estimate of $11.80 billion. Abbott Laboratories had a net margin of 14.72% and a return on equity of 17.94%. The business’s revenue was up 4.4% compared to the same quarter last year. During the same quarter last year, the firm earned $1.34 EPS. Abbott Laboratories has set its Q1 2026 guidance at 1.120-1.180 EPS and its FY 2026 guidance at 5.550-5.800 EPS. Analysts predict that Abbott Laboratories will post 5.14 earnings per share for the current year.

Abbott Laboratories Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, February 13th. Stockholders of record on Thursday, January 15th will be paid a $0.63 dividend. This is a boost from Abbott Laboratories’s previous quarterly dividend of $0.59. The ex-dividend date of this dividend is Thursday, January 15th. This represents a $2.52 annualized dividend and a dividend yield of 2.3%. Abbott Laboratories’s dividend payout ratio is currently 67.74%.

Wall Street Analysts Forecast Growth

Several research firms have commented on ABT. BTIG Research cut their price objective on Abbott Laboratories from $145.00 to $140.00 and set a “buy” rating for the company in a research note on Friday, January 23rd. Oppenheimer reduced their price objective on Abbott Laboratories from $140.00 to $132.00 and set an “outperform” rating for the company in a research note on Friday, January 23rd. Raymond James Financial lowered their target price on shares of Abbott Laboratories from $146.00 to $130.00 and set an “outperform” rating on the stock in a research note on Friday, January 23rd. Royal Bank Of Canada reduced their target price on shares of Abbott Laboratories from $147.00 to $135.00 and set an “outperform” rating for the company in a research report on Friday, January 23rd. Finally, William Blair upgraded shares of Abbott Laboratories to a “strong-buy” rating in a research report on Thursday, November 20th. One investment analyst has rated the stock with a Strong Buy rating, sixteen have given a Buy rating and four have assigned a Hold rating to the company. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and a consensus price target of $140.75.

Abbott Laboratories Profile

Abbott Laboratories is a global healthcare company headquartered in Abbott Park, Illinois, that develops, manufactures and markets a broad portfolio of medical products and services. Founded in 1888, Abbott operates through multiple business areas that focus on diagnostics, medical devices, nutritionals and established pharmaceuticals. The company supplies hospitals, clinics, laboratories, retailers and direct-to-consumer channels with products intended to diagnose, treat and manage a wide range of health conditions.

In diagnostics, Abbott provides laboratory and point-of-care testing platforms and assays used to detect infectious diseases, chronic conditions and biomarkers; its Alinity family of instruments and rapid-test solutions are examples of this capability.